| Relaxed Regulations at the State and Federal level have helped behavioral health providers deliver services via telehealth. Here is an executive summary of these regualtions. | 06/20 Relaxed Regulations Executive Summary |
| Interpreter Services: The HCA has created this
Apple Health (Medicaid) interpreter services policy during COVID-19 pandemic | Apple Health (Medicaid) interpreter services policy during COVID-19 pandemic |
| ABA Policy & Billing: Click here for Apple
Health (Medicaid) Applied Behavior Analysis (ABA) policy and billing during the
COVID-19 pandemic | Applied Behavioral Analysis (ABA) policy and billing |
| CMS emergencies webpage, which currently
contains the latest information on Coronavirus Waivers & Flexibilities;
guidance on clinical & technical, billing & coding, survey &
certification, coverage, provider enrollment, Medicaid & CHIP, marketplace
plan, MA plan, open payments, as well as partner & stakeholder resources
and consumer information. | CMS Current Emergencies page |
| Opioid Treatment Program: The HCA created this COVID-19 and opioid treatment programs frequently asked questions.
It is meant to support opioid treatment program (OTP) medical directors relating to the corona virus (COVID-19) situation in Washington. This guidance contains recommendations and resources from
state and federal partners.
| HCA COVID-19 and Opioid Treatment Programs |
| HCA’s
Division of Behavioral Health and Recovery (DBHR) created this behavioral
health provider COVID-19 information/guidance document, based on the questions
presented during the weekly webinars and emails.
Check
this document regularly because things change in a few hours with Federal and
state government guidance. | HCA Weekly Update for Behavioral Health Providers |
| HIPAA: This HHS webpage provides information on privacy rules during emergency situations.
There is a link to HHS Office for Civil Rights (OCR) guidance that helps explain civil rights laws as well as how the HIPAA Privacy Rule allows patient information to be shared in the outbreak of infectious disease and to assist patients in receiving the care they need. | HHS waiving waive potential HIPAA penalties |
| Confidentiality (42 CFR Part 2): ASAM has developed
this summary of “Changes to 42 CFR Part 2 in the Coronavirus Aid, Relief, and
Economic Security (CARES) Act of 2020”
There is also a helpful compilation of Resources. | https://www.asam.org/advocacy/federal-advocacy/standardize-the-delivery-of-individualized-addiction-treatment/confidentiality-(42-cfr-part-2)-new |
| Signature Requirements: The
HCA has developed these signature requirements for delivery of prescribed medications
during COVID-19 pandemic | https://www.hca.wa.gov/assets/billers-and-providers/signature-requirements-pharmacy.pdf |
| Buprenorphine: The
HCA created this FAQ document for COVID-19 and prescribers of buprenorphine
containing products in office based opioid treatment settings It is meant to
support prescribers of buprenorphine containing products in office based opioid
treatment settings relating to the coronavirus (COVID-19) situation in
Washington. This interim guidance contains recommendations and resources.
If you have additional questions, please email them to Washington State
Opioid Treatment Authority Jessica Blosejessica.blose@hca.wa.gov. | Prescribers of buprenorphine containing products in office based opioid treatment settings |
